You are here
Dr Martin Chasen - Section Editor
Medical Director of Pallatiative Care
at WOHS (Wiliam Osler Health System)
Brampton, Ontario, Canada
Dr. Martin Chasen is currently the Medical Director of Palliative Care, at WOHS (William Osler Health System), previously Medical Director, Palliative Care, The Ottawa Hospital Cancer Centre and the Palliative Rehabilitation Program at Élisabeth Bruyère Hospital, Ottawa.
Dr. Chasen, born in Pretoria, South Africa completed his undergraduate training in medicine and surgery at the University of Pretoria in 1983, later obtaining a specialist degree in Internal Medicine and Medical Oncology and Master of Philosophy (Palliative Medicine) at the University of Cape Town, South Africa.
Dr. Chasen is founding member of the palliative care working group of the European Society of Medical Oncology and faculty member of ESMO education. In 2009, Dr. Chasen was Team Leader and Physician, Cancer Nutrition & Rehabilitation Program at McGill University Hospital Complex obtained “Supra regionale de niveau 3” status for the PQCCC. In 2013, Dr. Chasen and the team at Ottawa Hospital cancer centre achieved ESMO Designated Centre of Integrated Oncology and Palliative care.
He currently holds professorships at the Universities of Toronto, Ottawa and McGill.
He has in excess of 100 peer reviewed publications, abstracts and book chapters. Dr. Chasen is the principle investigator of CIHR (Canadian Institutes of Health Research) involving national and international investigators. This MENAC (The Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia) trial will investigate the addition of the multimodal intervention for patients receiving standard chemotherapy for metastatic cancer. He was also one of the chief investigators for the initial clinical trials on the use of Rolapitant-a novel NKI inhibitor in the treatment of chemotherapy induced nausea and vomiting.
Dr. Chasen has lectured nationally and internationally on rehabilitation of patients with cancer, approaches to treatment of patients with cachexia, chemotherapy induced nausea and vomiting, survivorship and symptom relief.